Bipartisan Senators Release Committee Report on Drug Pricing Investigation

This report is the culmination of the Senate Aging Committee's year-long, bipartisan investigation into the egregious price increases on a number of decades-old drugs acquired by pharmaceutical companies that act more like hedge funds. We must work to stop the bad actors who are driving up the prices of drugs that they did nothing to develop at the expense of patients just because, as one executive essentially said, “because I can.” “The hedge fund model of drug pricing is predatory, and immoral for the patients and taxpayers who ultimately foot the bill—especially for generic drugs that can be made for pennies per dose,” Ranking Member McCaskill said. “We’ve got to find ways to increase competition for medicines and ensure that patients and their families aren’t being gouged.”       Related StoriesKmart Settles Whistleblower Case About Inflated PricesHow 2016 Drug Spending Stacks UpPhRMA Releases Report on Financial Flow in Pharmaceutical Industry 
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs